Depressive- and anxiety-like behaviors were measured in WT and HIV-1 tg rats receiving daily oral dosing of meloxicam.

<p><i>A,B</i>) In the Porsolt forced swim test, meloxicam treated WT and HIV-1 tg rats showed similar latencies to first float (<i>p</i>>0.05); however, HIV-1 tg rats spent more time immobile compared to WT controls (*<i>p</i><0.05). <i>C,D</i>) Similarly, in the social interaction test, meloxicam treated WT and HIV-1 tg rats showed no differences in their time to approach a stimulus rat (<i>p</i>>0.05); however, overall, meloxicam-treated HIV-1 tg rats spend less time interacting (*<i>p</i><0.05). <i>E,F</i>) In the open field test, meloxicam treated HIV-1 tg rats showed no differences in overall locomotion (<i>p</i>>0.05), but did show a significant decrease in distance traveled in the center of the open field, as compared to WT rats (*<i>p</i><0.05). Data are presented as mean ± SEM.</p>